ABSTRACT
ObjectiveTo investigate the clinical efficacy and surgical experience of hermo-expandable metallic prostate stent in the treatment of elderly high-risk BPH patients.MethodsRetrospective analysis was performed on 38 patients with BPH who underwent implantation of hermo-expandable metallic prostate stent from January 2017 to October 2018 in the General Hospital of Eastern Theater Command. The patients were 72 to 89 years old, with preoperative international prostatic symptom score (IPSS) of 25.6±4.1 points, maximum flow rate of urine (MRF) of (4.8±1.2) mL/s, and residual urine volume (RUV) (160.7±70.5) mL. Urinary catheters were placed in 7 patients for 4-8 days due to acute urinary retention.ResultsExcept for the failure in one case, all 37 patients were successfully implanted with the prostate stent at one time, and they urinated immediately after the operation without serious operation-related complications. Follow-up was conducted for 3 months, and the IPSS and RUV of the 37 patients were (15.6±4.3) and (40.7±12.9) mL respectively, which were significantly lower than those before the operation (P<0.05). MRF was (11.1±4.3) mL/s, significantly higher than that before surgery (P<0.05). 22 cases in this group were followed up for 2 years, and their IPSS, MRF and RUV were all stable.ConclusionThe thermo-expandable metallic prostate stent for the treatment of dysuria caused by BPH is effective, reliable and less traumatic. It is a preferred choice for the treatment of the aged BPH patients who are at a high risk and not suitable for surgery.
ABSTRACT
Objective@#To investigate the surgical techniques and clinical effect of Memokath transurethral spiral thermo-expandable prostatic stent (STEPS) implantation in the treatment of BPH.@*METHODS@#From January 2017 to January 2018, 26 BPH patients underwent Memokath transurethral STEPS implantation, 9 under the flexible cystoscope and the other 17 under the rigid cystoscope. The patients were aged 62－91 years old, with a prostate volume of 32－78 ml, postvoid residual urine volume (PVR) of (67.3 ± 11.2) ml, maximum urinary flow rate (Qmax) of (6.3 ± 1.8) ml/s, and IPSS score of 26.7 ± 5.7. Eight of the patients had preoperative urinary retention, of whom, 6 received catheterization and 2 had undergone cystostomy for bladder fistula before STEPS implantation.@*RESULTS@#The operations lasted 15－30 minutes and were successfully completed in 24 cases while stent-shedding occurred in the other 2. Twenty-two of the patients achieved spontaneous urination immediately after surgery and 2 experienced bladder clot embolism. At 3 month after surgery, 24 of the patients showed significant improvement in PVR (［21.4 ± 7.7］ ml), Qmax (［18.3 ± 4.7］ ml/s) and IPSS (8.3 ± 2.1), and 13 exhibited no statistically significant difference from the baseline in the IIEF-5 score (14.1 ± 1.1 vs 14.3 ± 1.0, P > 0.05). At 12 months, all the patients were found with markedly improved urination but no adverse events except recurrent urinary tract infection in 2 cases.@*CONCLUSIONS@#Memokath STEPS implantation, with its advantages of simple operation, high safety, definite effectiveness, non-influence on sexual function, is a new effective surgical option for the treatment of BPH.
ABSTRACT
Objective@#To investigate the value of real-time RNA simultaneous amplification and testing (SAT) in the detection of Ureaplasma urealyticum (UU) in the semen of infertile males and its clinical significance.@*METHODS@#We collected semen samples from 542 infertility patients and 120 normal fertile men as controls in the Andrology Clinic of Nanjing General Hospital from March to September 2015. We detected UU infection in the samples using the culture method and SAT technology, respectively.@*RESULTS@#All the UU positive cases (except 4 false positive cases) detected by the culture method were also shown to be positive in SAT. The UU detection rate of SAT was significantly higher than that of the culture method both in the infertility patients (54.1 vs 19.7%, P<0.05) and in the normal controls (42.5 vs 12.5%, P<0.05).@*CONCLUSIONS@#SAT is a rapid and accurate method for detecting UU infection in semen samples, with a higher sensitivity and accuracy than the culture method, and it can also be used to evaluate the therapeutic effects. However, the culture method has its own advantages, such as low requirement of technical equipment, easy operation, and possibility of drug sensitivity test at the same time. Therefore, SAT and the culture method can be used alternatively according to the clinical need.
Subject(s)
Humans , Male , Andrology , Infertility, Male , Microbiology , Nucleic Acid Amplification Techniques , RNA, Bacterial , Semen , Chemistry , Microbiology , Semen Analysis , Ureaplasma Infections , Diagnosis , Ureaplasma urealyticum , GeneticsABSTRACT
From January 2008 to January 2013, 11 patients with central renal tumors underwent ultrasound-guided open nephron sparing surgery (ONSS) without renal artery occlusion. We removed the lesions, and the cut edges of the tumors were negative. Thus, we deduced that ultrasound-guided ONSS is suitable for the cases with obscure tumor boundary or multiple lesions. It could achieve the purpose of thoroughly removing lesions, as well as to expand the application range of nephron sparing surgery.
ABSTRACT
From January 2008 to January 2013, 11 patients with central renal tumors underwent ultrasound-guided open nephron sparing surgery (ONSS) without renal artery occlusion. We removed the lesions, and the cut edges of the tumors were negative. Thus, we deduced that ultrasound-guided ONSS is suitable for the cases with obscure tumor boundary or multiple lesions. It could achieve the purpose of thoroughly removing lesions, as well as to expand the application range of nephron sparing surgery.
Subject(s)
Female , Humans , Male , Arterial Occlusive Diseases , Carcinoma, Renal Cell , General Surgery , Kidney Neoplasms , General Surgery , Nephrons , General Surgery , Postoperative Complications , Renal Artery , Pathology , General Surgery , Surgery, Computer-Assisted , Methods , UltrasonographyABSTRACT
<p><b>OBJECTIVE</b>To compare robot-assisted laparoscopic radical prostatectomy (RALRP) with laparoscopic radical prostatectomy (LRP) in the treatment of prostate cancer and investigate the clinical application value of RLRP.</p><p><b>METHODS</b>We retrospectively analyzed 70 cases of prostate cancer treated by RALRP and another 32 cases treated by LRP. We compared the operation time, intraoperative blood loss and transfusion, catheter-indwelling time, postoperative hospital stay, incisal margin positive rate, biochemical recurrence, and normal postoperative urinary continence and penile erectile function between the two groups of patients.</p><p><b>RESULTS</b>All the operations were successfully accomplished. RALRP exhibited a significant superiority over LRP in intraoperative blood loss and transfusion, catheter-indwelling time, and postoperative hospital stay, urinary continence and erectile function (P < 0.05).</p><p><b>CONCLUSION</b>Robot-assisted laparoscopic radical prostatectomy, with its advantages of few postoperative complications and well-preserved urinary continence and penile erectile function, is an effective, safe and minimally invasive surgical option for prostate cancer.</p>
Subject(s)
Humans , Male , Blood Loss, Surgical , Laparoscopy , Length of Stay , Operative Time , Penile Erection , Postoperative Complications , Postoperative Period , Prostatectomy , Methods , Prostatic Neoplasms , General Surgery , Retrospective Studies , Robotic Surgical Procedures , MethodsABSTRACT
<p><b>OBJECTIVE</b>To examine the effect of ONO-AE3-208, an EP4 antagonist, on the formation of bone metastasis from prostate cancer in mice.</p><p><b>METHODS</b>Thirty-four 6-week old nude mice were divided into an experimental and a control group of equal number to be treated by intraperitoneal injection of ONO-AE3-208 and double distilled water, respectively. Then PC3/LUC cells were constructed by stably transfecting luciferin to prostate cancer PC3 cells and inoculated into the left ventricle of the mice to establish an animal model of systemic bone metastasis. The time of metastasis formation, photon tumor burdens, and changes of the survival curves after modeling were compared between the two groups of mice.</p><p><b>RESULTS</b>At 30 days after modeling, bioluminescence imaging analysis showed that the photon tumor burdens were significantly increased in a time-dependent manner in the control group in comparison with those in the experimental group (P < 0.01). The rate of metastasis formation was significantly higher in the former than in the latter (93.3% vs 33.3%, P < 0.001). The median time of metastasis formation was 29 d (95% CI 26.547 - 35.262) in the experimental animals as compared with 21 d (95% CI 17.213 -24.787) in the controls (P < 0.001).</p><p><b>CONCLUSION</b>EP4 antagonist ONO-AE3-208 can inhibit the formation of bone metastasis from prostate cancer in mice.</p>
Subject(s)
Animals , Humans , Male , Mice , Bone Neoplasms , Cell Line, Tumor , Disease Models, Animal , Mice, Nude , Naphthalenes , Pharmacology , Neoplasms, Experimental , Phenylbutyrates , Pharmacology , Prostatic Neoplasms , PathologyABSTRACT
<p><b>OBJECTIVE</b>To study the causes, clinical manifestations, treatment and prevention of calculus that develops in the prostatic cavity after transurethral resection of the prostate.</p><p><b>METHODS</b>We reported 11 cases of calculus that developed in the prostatic cavity after transurethral resection or transurethral plasmakinetic resection of prostate. The patients complained of repeated symptoms of frequent micturition, urgent micturition and urodynia after operation, accompanied with urinary tract infection and some with urinary obstruction, which failed to respond to anti-infective therapies. Cystoscopy revealed calculi in the prostatic cavity, with eschar, sphacelus, uneven wound surface and small diverticula in some cases. After diagnosis, 1 case was treated by holmium laser lithotripsy and a second transurethral resection of the prostate, while the other 10 had the calculi removed under the cystoscope, followed by 1 -2 weeks of anti-infective therapy.</p><p><b>RESULTS</b>After treatment, all the 11 cases showed normal results of routine urinalysis, and no more symptoms of frequent micturition, urgent micturition and urodynia. Three- to six-month follow-up found no bladder irritation symptoms and urinary tract infection.</p><p><b>CONCLUSION</b>Repeated symptoms of frequent micturition, urgent micturition, urodynia and urinary tract infection after transurethral resection of the prostate should be considered as the indicators of calculus in the prostatic cavity, which can be confirmed by cystoscopy. It can be treated by lithotripsy or removal of the calculus under the cystoscope, or even a second transurethral resection of the prostate. For its prevention, excessive electric coagulation and uneven wound surface should be avoided and anti-infection treatment is needed.</p>
Subject(s)
Aged , Humans , Male , Middle Aged , Prostatic Diseases , Therapeutics , Transurethral Resection of Prostate , Methods , Urinary Calculi , TherapeuticsABSTRACT
<p><b>OBJECTIVE</b>To investigate the effects of the downregulated expression of the prostate androgen regulated (PAR) gene on the cell cycle and apoptosis of PC3 cells as well as on the expression level of Bcl-2/Bax.</p><p><b>METHODS</b>After transfecting PC3 cells with small interfering RNA (siRNA) targeting PAR, we detected the inhibitory effect of PAR depletion on the proliferation of the PC3 cells by MTT assay, determined their apoptosis by flow cytometry, and measured the expression levels of Bcl-2 and Bax by Western blot.</p><p><b>RESULTS</b>The expression of PAR was suppressed by siRNA, the G2-M phase PC3 cells were increased to (29.95 +/- 3.25)%, and the apoptosis of the cells was enhanced to (20.61 +/- 2.73)%, with statistically significant difference from the control group (P < 0.01). Western blot showed a decreased expression of Bcl-2, an increased expression of Bax, and an elevated ratio of Bax to Bcl-2.</p><p><b>CONCLUSION</b>Downregulation of the PAR expression increases the Bax/Bcl-2 ratio and Bax expression, and thus induces the G2-M phase arrest and apoptosis of PC3 cells.</p>
Subject(s)
Humans , Male , Apoptosis , Cell Cycle Checkpoints , Cell Line, Tumor , Gene Expression Regulation, Neoplastic , Membrane Proteins , Genetics , Metabolism , Neoplasm Proteins , Genetics , Metabolism , Prostate , Metabolism , Prostatic Neoplasms , Genetics , Metabolism , Pathology , Proto-Oncogene Proteins c-bcl-2 , Genetics , Metabolism , RNA, Small Interfering , Genetics , bcl-2-Associated X Protein , Genetics , MetabolismABSTRACT
<p><b>OBJECTIVE</b>To evaluate the correlation of the single nucleotide polymorphisms (SNPs) of the CYP1A2 gene with the stages and grades of prostate cancer (PCa).</p><p><b>METHODS</b>We conducted gene sequencing of the rs2069514-3859 (A > G) and rs2069525-1707 (C >T) alleles in the CYP1A2 gene in 253 patients with benign prostatic hyperplasia (BPH) and 206 patients with PCa treated by castration therapy, and statistically analyzed their correlations with the genotypes, stages and grades of prostate cancer.</p><p><b>RESULTS</b>The incidences of the 2 CYP1A2 SNPs showed no significant difference between the BPH and the castrated PCa patients (P > 0.05), and their genotypes were not correlated with the stages of PCa (P > 0.05). The Gleason scores were mostly <7 in the PCa patients with genotypes containing C in the rs2069525-1707 (C > T) allele (P = 0.030, OR = 4.658, 95% CI: 1.222 - 17.754).</p><p><b>CONCLUSION</b>SNPs of the CYP1A2 gene may have some correlations with the pathologic stages of PCa, but their mechanisms and clinical significance need to be further confirmed.</p>
Subject(s)
Aged , Aged, 80 and over , Humans , Male , Middle Aged , Cytochrome P-450 CYP1A2 , Genetics , Genotype , Polymorphism, Single Nucleotide , Prostatic Neoplasms , Genetics , PathologyABSTRACT
<p><b>OBJECTIVE</b>To evaluate the effects of methylation inhibitor 5-Aza-2'-Deoxycytidine (5-aza-2dc) and docetaxel (DT), alone or in combination, on the proliferation, migration, apoptosis and cell cycles of the human prostate cancer cell line PC3, and to investigate the possible mechanisms of these two drugs acting on prostate cancer in vitro.</p><p><b>METHODS</b>Four groups were designed in this experiment: control, 5-aza-2dc, DT, and 5-aza-2dc + DT. The inhibitory effect of 5-aza-2dc and/or DT on the proliferation, migration and invasiveness of PC3 cells was detected by MTT, wound healing assay and cell migration assay, respectively. The apoptosis of the PC3 cells and its relationship with cell cycles were determined by Annexin V-FITC/PI assay and flow cytometry.</p><p><b>RESULTS</b>5-aza-2dc and/or DT significantly increased the inhibition rate of the PC3 cells, decreased their migration distance and reduced the number of the cells that invaded the lower chamber, most significantly in the 5-aza-2dc + DT group (P < 0.05). The cell apoptosis rates of the control, 5-aza-2dc, DT and 5-aza-2dc + DT groups were (10.65 +/- 0.39)%, (16.60 +/- 0.67)%, (17.95 +/- 1.08)% and (22.98 +/- 1.18)%, respectively, with the most significant increase in the combination group (P < 0.05). Combined medication of 5-aza-2dc and DT remarkably reduced the number of cells in the G0/G1 phase, and increased that in the G2/M phase (P < 0.05).</p><p><b>CONCLUSION</b>5-aza-2dc and DT, either alone or in combination, can significantly inhibit the proliferation, migration and invasiveness of PC3 cells in vitro, as well as induce their apoptosis and arrest their cell cycles in the G2/M phase, with even more significant effect when used in combination than applied alone.</p>
Subject(s)
Humans , Male , Apoptosis , Cell Cycle , Cell Line, Tumor , Cell Movement , Cell Proliferation , Deoxycytidine , Pharmacology , Drug Synergism , Taxoids , PharmacologyABSTRACT
<p><b>OBJECTIVE</b>To explore the feasibility of the treatment of hypospadias with penile and scrotal skin flaps.</p><p><b>METHODS</b>Twenty-three hypospadias patients aged 3.5-19 (mean 6. 8) years underwent urethroplasty with penile and scrotal skin flaps. All were followed up for 6 years and analyzed retrospectively.</p><p><b>RESULTS</b>Of the total number of patients, 21 (91.3%) succeeded in one operation and the other 2 developed complications, including urethral fistula and urethral structure.</p><p><b>CONCLUSION</b>Penile and scrotal skin, advantageous for its adequacy, rich blood supply and contribution to high success rate of surgery, is believed to be the first choice for urethroplasty in the treatment of hypospadias.</p>
Subject(s)
Adolescent , Adult , Child , Child, Preschool , Humans , Male , Hypospadias , General Surgery , Penis , General Surgery , Retrospective Studies , Scrotum , General Surgery , Skin Transplantation , Surgical FlapsABSTRACT
<p><b>OBJECTIVE</b>To investigate the regulatory effect of the nonsteroidal anti-inflammatory drug NS398 on the expression of the RECK gene in the animal model of prostate cancer.</p><p><b>METHODS</b>Nude mouse models of prostate cancer were divided into an experimental and a control group, the former fed with NS398 at 0.1 mg/g per day for 10, 20 and 30 days, while latter left without medication. All the mice were killed at 30 days, the mRNA expressions of RECK and MMP-9 in the tumor tissues measured by RT-PCR, and the protein level of RECK evaluated by Western blot.</p><p><b>RESULTS</b>Both the mRNA and protein expressions of RECK were increased, while the level of MMP-9 decreased, in an obviously time-dependent manner in the experimental group as compared with the control.</p><p><b>CONCLUSION</b>NS398 obviously inhibits the pathogenesis and metastasis of prostate cancer, which may be attributed to its induction of the expression of the RECK gene and suppression of the expression of MMP-9.</p>
Subject(s)
Animals , Humans , Male , Mice , Anti-Inflammatory Agents, Non-Steroidal , Pharmacology , GPI-Linked Proteins , Metabolism , Gene Expression Regulation , Matrix Metalloproteinase 9 , Metabolism , Mice, Nude , Nitrobenzenes , Pharmacology , Sulfonamides , Pharmacology , Tumor Cells, CulturedABSTRACT
<p><b>OBJECTIVE</b>To assess the safety of hyperbaric oxygen in the treatment of radiation-induced hemorrhagic cystitis in patients with prostate cancer, and to investigate its effect on the growth of indolent prostate cancer in vivo.</p><p><b>METHODS</b>Thirty severe combined-immunodeficient mice received subcutaneous injection of human prostate cancer LNCaP cells. Then they were randomized to an experimental and a control group and exposed to 20 sessions of hyperbaric oxygen and normobaric air, respectively, followed by a 4-week observation on the growth of the transplanted tumors and analyses of their histopathological features at 28 days, including the volume, microvessel density (CD34), apoptosis markers (p53 and p27 proteins) and the proliferation index (Ki-67) of the LNCaP tumors.</p><p><b>RESULTS</b>On the 28th day after tumor vaccination, the tumor volume was (120 +/- 7.9) mm3 in the HBO and (122 +/- 8.2) mm3 in the control group; the microvessel density and the expressions of Ki-67, p53 and p27 were 39.3 +/- 5.2, (78.1 +/- 7.6)%, (40.4 +/- 6.2)% and (63.7 +/- 5.1)% in the former, and 36.2 +/- 4.9, (75.3 +/- 8.4)%, (44.2 +/- 5.7)% and (61.5 +/- 5.5)% in the latter. There were no significant differences in all the indexes above between the two groups (P > 0.05).</p><p><b>CONCLUSION</b>Hyperbaric oxygen did not promote the growth of indolent prostate cancer in the murine model, nor did it have any significant effect on the new vessels.</p>
Subject(s)
Animals , Humans , Male , Mice , Cell Line, Tumor , Hyperbaric Oxygenation , Mice, SCID , Prostatic Neoplasms , Xenograft Model Antitumor AssaysABSTRACT
<p><b>OBJECTIVE</b>To determine the clinicopathological characteristics, treatment and prognostic features of prostatic small cell carcinoma (SCC).</p><p><b>METHODS</b>One case of SCC was reported, and the relevant literature was reviewed and analyzed.</p><p><b>RESULTS</b>Prostate specific antigen (PSA) was increased (39.26 ng/ml); computed tomography revealed multiple nodules in the retroperitoneum and cavita pelvis; ECT showed multiple osseous metastasis; and needle biopsy of the prostate confirmed SCC. Negative expressions of PSA, Bcl-2 and P504S were found by immunohistochemical staining. The cancer was clinically staged at T4N1M1. Because the patient was beyond surgery and refused chemotherapy, Zadaxin (thymosin alpha 1) was given to relieve the clinical symptoms. The patient died five months after the diagnosis.</p><p><b>CONCLUSION</b>SCC is a rare subset of prostate cancer, with high malignancy, rapid growth, fast metastasis and very poor prognosis. Its diagnosis relies on pathological examinations. PSA cannot be a specific tumor marker of SCC, but some immunophenotypes may help its differential diagnosis. As for its treatment, surgery should be considered in the early stage; neither hormonal therapy nor chemotherapy can afford a favorable prognosis, although the latter may effect a short-term relief of the clinical symptoms.</p>
Subject(s)
Aged, 80 and over , Humans , Male , Carcinoma, Small Cell , Metabolism , Pathology , Lymphatic Metastasis , Prostate-Specific Antigen , Metabolism , Prostatic Neoplasms , Metabolism , Pathology , Retrospective StudiesABSTRACT
<p><b>OBJECTIVE</b>To investigate the anti-tumor effect of the endothelin A receptor antagonist BQ123 on human prostate cancer cell line PC-3M in vitro by observing its impact on the proliferation and apoptosis of human prostate cancer cells.</p><p><b>METHODS</b>The inhibiting effect of BQ123 on the proliferation of PC-3M cells was observed by MTT assay, erosion trace test and Transwell chamber chemotaxis assay, and its induction of their apoptosis determined by Annexin V-FITC/PI staining and cytometry.</p><p><b>RESULTS</b>BQ123 exhibited increased inhibition of PC-3M cells in a time-dependent manner, with inhibition rates of 22.32%, 44.88% and 64.47% at 24 h, 48 h and 72 h, respectively (P < 0.05). The migration distances of the PC-3M cells in the BQ123 group were (103.42 +/- 75.63) microm, (243.75 +/- 121.53) microm and (422.07 +/- 36.01) microm at 12 h, 24 h and 48 h, obviously lower than (162.93 +/- 19.87) microm, (317.19 +/- 43.19) microm and (692.74 +/- 40.84) microm in the control group (P < 0.05). The number of the PC-3M cells that invaded the inferior chamber in the BQ123 group was (79.2 +/- 9.58), significantly decreased as compared with (92.6 +/- 5.94) in the control (P < 0.05). The apoptosis rate of PC-3M exposed to BQ123 was (15.03 +/- 0.93)%, significantly higher than (9.38 +/- 1.37)% in the control (P < 0.05). The ratio of PC-3M cells in different cycles showed no significant differences.</p><p><b>CONCLUSION</b>BQ123 inhibits the proliferation of PC-3M cells and induces their apoptosis in vitro, which may give a new idea on the studies of prostate cancer therapies.</p>
Subject(s)
Humans , Male , Apoptosis , Cell Line, Tumor , Cell Proliferation , Endothelin A Receptor Antagonists , Peptides, Cyclic , Pharmacology , Prostatic NeoplasmsABSTRACT
<p><b>OBJECTIVES</b>To investigate the regulative effect of the nonsteroidal anti-inflammatory drug NS398 on the RECK gene in the prostate carcinoma strain DU145.</p><p><b>METHODS</b>DU145 was treated with various concentrations of NS398 for 48 hours. The mRNA level was measured by RT PCR technique and the expression of the RECK protein determined by Western blot.</p><p><b>RESULTS</b>The mRNA level of the RECK gene was obviously higher, while the MMP9 level markedly lower in the treated group than in the control, and so was the expression of the RECK protein.</p><p><b>CONCLUSION</b>NS398 induces the expression of the RECK gene, which might be the mechanism of its anti-tumor effect.</p>
Subject(s)
Animals , Cattle , Humans , Male , Anti-Inflammatory Agents, Non-Steroidal , Pharmacology , Blotting, Western , Cell Line, Tumor , GPI-Linked Proteins , Gene Expression Regulation, Neoplastic , Membrane Glycoproteins , Genetics , Nitrobenzenes , Pharmacology , Prostatic Neoplasms , Genetics , Metabolism , Pathology , RNA, Messenger , Genetics , Metabolism , Reverse Transcriptase Polymerase Chain Reaction , Sulfonamides , PharmacologyABSTRACT
<p><b>OBJECTIVE</b>To investigate the inhibitory effect of grape seed extract (GSE) on the growth of prostate cancer PC-3 cells.</p><p><b>METHODS</b>PC-3 cells were treated with GSE at the concentration of 100, 200 and 300 microg/ml for 24, 48 and 72 hours, respectively. The the inhibitory effect of GSE on the growth of the PC-3 cells and the kidney cells of SD rats was determined by MTT reduction assay, with primarily cultured kidney cells of 1-3 days old SD rats as the normal control.</p><p><b>RESULTS</b>GSE significantly inhibited the growth of PC-3 cells in a concentration- and time-dependent manner, but had only a mild inhibitory effect on the kidney cells.</p><p><b>CONCLUSION</b>GSE inhibits the growth of prostate cancer PC-3 cells and can be used as a new drug for the treatment of prostate cancer.</p>
Subject(s)
Animals , Humans , Male , Rats , Cell Line, Tumor , Cell Proliferation , Cell Survival , Cells, Cultured , Dose-Response Relationship, Drug , Kidney , Cell Biology , Plant Extracts , Pharmacology , Prostatic Neoplasms , Pathology , Rats, Sprague-Dawley , Seeds , Chemistry , Time Factors , Vitis , ChemistryABSTRACT
<p><b>OBJECTIVE</b>To investigate the anti-tumor effect of celecoxib on human prostate cancer cell line PC-3 in vitroby observing its effects on the proliferation and apoptosis of PC-3 cells.</p><p><b>METHODS</b>The effects of Celecoxib on the proliferation of PC-3 cells were observed by MTT assay, erosion trace test and Transwell-chamber chemotaxis assay, and their apoptosis detected by Annexin V/FITC fluorescent staining and flow cytometry.</p><p><b>RESULTS</b>With the increasing concentration and exposure time, Celecoxib exhibited an increased rate of inhibition on PC-3 cells in a dose- and time-dependent manner (P < 0.05). Compared with the controls, the migration distance of the PC-3 cells and the number of the PC-3 cells that invaded the inferior chamber were significantly decreased in the 100 gm/L Celecoxib group (P < 0.05). Celecoxib induced the apoptosis of PC-3 cells and, at 100 microm/L, significantly increased the percentage of PC-3 cells in the G0/G1 phase but decreased it in the S phase as compared with the control group (P < 0.05).</p><p><b>CONCLUSION</b>Celecoxib inhibits the proliferation and induces the apoptosis of PC-3 cells in vitro, which, as a new therapeutic for prostate cancer, well deserves further investigation.</p>
Subject(s)
Humans , Male , Apoptosis , Celecoxib , Cell Cycle , Cell Line, Tumor , Cell Proliferation , Cell Survival , Cyclooxygenase 2 Inhibitors , Pharmacology , Dose-Response Relationship, Drug , Flow Cytometry , Prostatic Neoplasms , Pathology , Pyrazoles , Pharmacology , Sulfonamides , Pharmacology , Time FactorsABSTRACT
<p><b>OBJECTIVE</b>To observe the morphological changes of prostate cancer PC-3 cells induced by grape seed extract (GSE).</p><p><b>METHODS</b>PC-3 cells were incubated with different concentrations of GSE (100, 200 and 300 microg/ml) for 24, 48 and 72 hours, and then observed for morphological changes by invert microscopy, HE staining and transmission electron microscopy.</p><p><b>RESULTS</b>The incubated PC-3 cells appeared round, small, wrinkled and broken under the invert microscope and exhibited the classical morphological characteristics of cell death under the electron microscope, including cell atrophy, increased vacuoles, crumpled nuclear membrane, and chromosome aggregation.</p><p><b>CONCLUSION</b>GSE can cause morphological changes and induce necrosis and apoptosis of PC-3 cells.</p>